To increase access to addiction medications . . .

Experts Back Value-Based Pricing, Fewer Prescribing Restrictions For MAT

By Beth Wang
December 5, 2018 at 11:03 AM
The Institute for Clinical Economic Review (ICER) on Monday (Dec. 3) issued a final report featuring recommendations for how to develop policy on and increase access to extended-release medications for addiction treatment. The report suggests: manufacturers align the prices of their medications with their clinical value; payers create flexible prior authorization criteria; and regulators eliminate restrictions on prescribing extended-release buprenorphine. The report also urges payers and policymakers to avoid legislative action favoring one form of medication over another. ICER also...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.